Audit: QRS - ACE-031 for Muscle Growth
Audit conducted on 13/09/2026 16:10 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells vs ER Therapeutic Protocol, time cells vs Practical Considerations / Expected Benefits, gates vs Key Interactions & Contraindications, markers and cadence vs Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried through: time_3_sub keeps “reported only as a directional trend”; risks/benefits speculative tiers retain their ER tier assignment. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected; action_3 keeps the ER’s “Never approved anywhere” and “not a standard of care”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit-Modifying and Risk-Modifying Factors are not surfaced anywhere; gates draw only from the ER’s Key Interactions & Contraindications section. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, NCT identifiers or author names in the QRS. All drug names (bimagrumab, clopidogrel, semaglutide, etc.) appear in the ER for the same fact. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | Only attribution is “Acceleron Pharma” in action_3_sub, taken from the ER Therapeutic Protocol bullet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s sober, evidence-limited register throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert, objective and data-driven; the negative signal is the ER’s own, presented without alarmism. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and thresholds; no prescriptive voice. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advisory constructions; the fixed template disclaimer carries the clinician-confirmation note. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise” or “guidance” phrasing in the body. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used; technical terms that appear (telangiectasias, eGFR, DXA) are ER monitoring/risk terms, not gratuitous jargon. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | All cells are short phrases; no sentence-length elaborations outside the sub lines. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing suits a risk-aware self-directed reader: identity testing, thresholds, stopping-relevant markers. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Weekly mucosal inspection, 8-12 week bloods and DXA at 12/24 weeks assume a willing, effortful reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not written for a general-population reader; assumes lab access and interpretation. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting mirrors the ER: mass without function, plus an unverifiable supply chain. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register maintained; “subcutaneous injection”, “adverse”-class terms and “injected” rather than “shot”. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings present verbatim: Protocol, Time to effect, Benefits, Risk & Side Effects, Monitoring, Qualitative Assessment, Contraindications, Key Interactions, High/Medium/Low/Speculative, Marker/Target/Why. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every template span is present. Repeatable spans expanded to marker_1..9_{name,target,why} and qualitative_item_1..5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Style block is byte-identical to the template; head, footer, override stylesheet link and the three website=”…” spans are unchanged. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section relevant to the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim (“Repeat-dose regimens studied”, “Single-dose range studied”, “No approved or practitioner-established protocol exists”); interaction labels likewise. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring marker names are verbatim from the ER biomarker table; tier and gate labels are ER headings/bullets. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji indicators anywhere in the file. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to phrase-level entries and no section is duplicated or extended; the single-sheet template structure is preserved. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment spans lines 2-14, immediately after <!doctype html> and before any other content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the preamble text precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside an HTML comment; no rendered element repeats it. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: ace_031_muscle_2026-0913-1436_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.11, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0913-1552, correct YYYY-MMDD-HHMM format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the actual filename ace_031_muscle_2026-0913-1436_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic = “ACE-031 for Muscle Growth”, the ER canonical_topic. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 09/13/2026, correctly derived from qrs_creation_date 2026-0913-1552. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model = “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the template subline; no AKA line, badge, version stamp or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion: mechanism, what moved, why development stopped, and supply integrity. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each of the four sentences maps to a distinct Conclusion passage. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “telangiectasias” is rendered as “clusters of widened small blood vessels”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sample sizes or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No percentages, effect sizes or statistical results. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All ten ER “Populations who should avoid ACE-031” bullets are present, plus the ER’s explicit absolute contraindication on other activin-pathway agents. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eleven <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing clauses stripped (e.g. “the population in which the program was halted”, “for whom the compound is prohibited at all times”). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and windows retained: 100 x 10^9/L, 52%/48%, 160/100 mmHg, 6 months, 18 years, von Willebrand disease / hemophilia. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated; the ER does identify populations to avoid the intervention. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER Key Interactions & Contraindications section. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Seven of the nine ER interaction bullets appear; oral anticoagulants and other activin-pathway agents are correctly omitted because both are covered in Contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale and mitigation sentences from the ER bullets are stripped; only the label and its drug list remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs preserved for every item, including the supplement lists built from the ER bullet bodies (vitamin E above 400 IU threshold retained). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated; the ER does identify interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Repeat-dose regimens, single-dose range and the absence of any approved protocol are the three actionable aspects; the remaining ER bullets are pharmacology or comparator context. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides at least three distinct actionable aspects, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields carry ER-derived content. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Skeletal muscle mass, bone mineral density and fat mass are the only outcomes with a time course in the ER. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High -> Medium -> Low, matching the ER benefit tiers. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields carry ER-derived content (29 days, 24 weeks, 24 weeks). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare outcome names only; no magnitudes, sponsors or study context. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The ER’s parenthetical and marker annotations (percentages, “Not Central to Muscle Growth”, “Conflicted”) are stripped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit sub-sections have items in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans are present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Bare risk names only; no frequencies or mechanism. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | Event frequencies (6/9, 5/9, 12/14) and mechanistic notes are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk sub-sections have items in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All nine ER biomarker-table rows are listed: hematocrit, hemoglobin, platelet count, ferritin, blood pressure, lean body mass, lumbar spine BMD, ALT, eGFR. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence populated with the ER’s schedule: 4 weeks then every 8-12 weeks, weekly skin/mucosal inspection, DXA at 12 and 24 weeks. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative bullets are reproduced. |
Issues 13/09/2026 16:10
Pass rate 100.00%. No issues found.
Issues 13/09/2026 16:00
- 1.1 / 7.3 — At-A-Glance overstates trial scope: “It enlarged muscle, raised bone density and reduced body fat in both human trials” (lines 435–436) attaches “in both human trials” to all three outcomes; the ER Conclusion (ER line 454) scopes that phrase to muscle only, and bone mineral density and fat mass were measured only in the Duchenne trial.
- 4.5 — Sheet exceeds the one-A4-page budget: Estimated rendered height is roughly double the printable A4 area — the Contraindications gate runs ~18 wrapped lines (lines 567–585), the Monitoring table ~19 wrapped rows plus a 2-line cadence (lines 637–776), and each Protocol and Time-to-effect sub wraps to 3–4 lines (e.g. lines 483–486, 503–506).
Fixes 13/09/2026 16:00
- 1.1 / 7.3 — At-A-Glance trial scope corrected: Rewrote the second sentence from “It enlarged muscle, raised bone density and reduced body fat in both human trials” to “It enlarged muscle in both human trials, and also raised bone density and reduced body fat”, restoring the ER Conclusion’s scoping of “in both human trials” to muscle only. Still 59 words.
- 4.5 — Protocol and Time-to-effect subs condensed: Trimmed all six sub-cells to shorter wording (e.g. action_3_sub from “ACE-031 was never approved anywhere and no clinic or physician prescribes it. Every regimen above was designed by Acceleron Pharma…” to “Never approved anywhere. Every regimen above was designed by Acceleron Pharma…”), cutting each from 3–4 wrapped lines to 2.
- 4.5 — Contraindications gate shortened: Compressed four items without dropping any qualifier — “within the previous 6 months” to “within 6 months”, “hematocrit above 52% in men or above 48% in women” to “hematocrit above 52% men, 48% women”, and the activin-pathway example list trimmed to four named agents.
- 4.5 — Key Interactions gate shortened: Trimmed the two supplement example lists (“high-dose fish oil…concentrated garlic extract…high-dose curcumin” to “fish oil…garlic extract…curcumin”; “creatine monohydrate, HMB, epicatechin-containing extracts” to “creatine, HMB, epicatechin extracts”), keeping every class and the vitamin E 400 IU threshold.
- 4.5 — Monitoring table and cadence condensed: Shortened all nine “Why” cells and the lean-body-mass target to single wrapped lines, and tightened the cadence sentence, removing roughly seven wrapped rows from the table.